{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=38", "query": { "condition": "Recurrent Gliomas", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 1033, "total_pages": 104, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=39&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=37&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T10:43:23.630Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07629089", "title": "VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Cancer" ], "interventions": [ { "name": "Vorasidenib", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Megan Mantica", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-06-30", "completion_date": "2035-06-30", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-22T10:43:23.630Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07629089" }, { "nct_id": "NCT00528437", "title": "Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumors" ], "interventions": [ { "name": "temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 46, "start_date": "2005-10", "completion_date": "2017-12-30", "has_results": true, "last_update_posted_date": "2021-07-08", "last_synced_at": "2026-10-22T10:43:23.630Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Lihue, Hawaii + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lihue", "state": "Hawaii" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00528437" }, { "nct_id": "NCT01806675", "title": "18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Male Breast Cancer", "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Brain Tumor", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Hypopharyngeal Cancer", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Laryngeal Cancer", "Recurrent Lip and Oral Cavity Cancer", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Nasopharyngeal Cancer", "Recurrent Non-small Cell Lung Cancer", "Recurrent Oropharyngeal Cancer", "Recurrent Pancreatic Cancer", "Recurrent Paranasal Sinus and Nasal Cavity Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Pancreatic Cancer", "Stage IV Renal Cell Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVB Colon Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVC Salivary Gland Cancer", "Tongue Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "18F-fludeoxyglucose (18F-FDG)", "type": "DRUG" }, { "name": "18F-FPPRGD2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanjiv Sam Gambhir", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2013-03-04", "completion_date": "2019-04", "has_results": true, "last_update_posted_date": "2019-10-03", "last_synced_at": "2026-10-22T10:43:23.630Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01806675" }, { "nct_id": "NCT02658981", "title": "Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "Recurrent Brain Neoplasm" ], "interventions": [ { "name": "Anti-LAG-3 Monoclonal Antibody BMS 986016", "type": "BIOLOGICAL" }, { "name": "Anti-PD-1", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Anti-CD137", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2016-08-24", "completion_date": "2023-10-03", "has_results": false, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-10-22T10:43:23.630Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02658981" }, { "nct_id": "NCT04408092", "title": "Study of the Effect of GM-CSF on Macrophages in Ependymoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Ependymoma, Recurrent Childhood", "Ependymoma" ], "interventions": [ { "name": "Granulocyte Macrophage Colony Stimulation Factor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 6, "start_date": "2013-06-25", "completion_date": "2023-07-21", "has_results": false, "last_update_posted_date": "2024-03-15", "last_synced_at": "2026-10-22T10:43:23.630Z", "location_count": 2, "location_summary": "Denver, Colorado • Orlando, Florida", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04408092" }, { "nct_id": "NCT03970447", "title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" }, { "name": "Paxalisib", "type": "DRUG" }, { "name": "VAL-083", "type": "DRUG" }, { "name": "VT1021", "type": "DRUG" }, { "name": "Troriluzole", "type": "DRUG" }, { "name": "ADI-PEG 20", "type": "BIOLOGICAL" }, { "name": "AZD1390", "type": "DRUG" }, { "name": "Tinostamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Global Coalition for Adaptive Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2250, "start_date": "2019-07-30", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-22T10:43:23.630Z", "location_count": 42, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03970447" }, { "nct_id": "NCT03034135", "title": "Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "Disulfiram/Copper", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cantex Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2017-03-09", "completion_date": "2018-07-10", "has_results": true, "last_update_posted_date": "2021-09-13", "last_synced_at": "2026-10-22T10:43:23.630Z", "location_count": 8, "location_summary": "Royal Oak, Michigan • St Louis, Missouri • Hackensack, New Jersey + 5 more", "locations": [ { "city": "Royal Oak", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03034135" }, { "nct_id": "NCT00003476", "title": "Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Brain Tumor" ], "interventions": [ { "name": "Antineoplaston therapy (Atengenal + Astugenal)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Months to 18 Years" }, "enrollment_count": 8, "start_date": "1996-03", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2017-08-24", "last_synced_at": "2026-10-22T10:43:23.630Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003476" }, { "nct_id": "NCT02748135", "title": "A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)" ], "interventions": [ { "name": "TB-403 20mg/kg", "type": "DRUG" }, { "name": "TB-403 50mg/kg", "type": "DRUG" }, { "name": "TB-403 100mg/kg", "type": "DRUG" }, { "name": "TB-403 175mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncurious NV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Months to 18 Years" }, "enrollment_count": 18, "start_date": "2016-05", "completion_date": "2020-10-06", "has_results": false, "last_update_posted_date": "2021-01-13", "last_synced_at": "2026-10-22T10:43:23.630Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Oakland, California • Hartford, Connecticut + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02748135" }, { "nct_id": "NCT02765165", "title": "Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors (Phase 1)", "Relapsed/Recurrent GBM (Phase 2)" ], "interventions": [ { "name": "USL311", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Proximagen, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2016-04", "completion_date": "2020-07-01", "has_results": true, "last_update_posted_date": "2021-07-23", "last_synced_at": "2026-10-22T10:43:23.630Z", "location_count": 5, "location_summary": "St Louis, Missouri • Oklahoma City, Oklahoma • Houston, Texas + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02765165" } ] }